LBRX LBRX Preclinical — Direct Research And Development Expenses

Similar metrics at other companies

MPLTPreclinical Program — Research And Development Expense

$5.52M-9.2%

RAPPPreclinical Programs External Expenses — Research And Development Expense

$4.29M+32.1%

BCRXResearch, discovery and preclinical programs — Research and Development Expense (Excluding Acquired in Process Cost)

$3.97M+30.4%

SRRKEarly Research — Research And Development Expense

$1.21M-16.8%

GERNResearch and clinical expenses — R&D

$13M-5.1%

ZYMEExpense for other preclinical and research programs — R&D

$7.26M+19.6%

Questions, answered.

What is LBRX's preclinical — direct research and development expenses?

LBRX (LBRX) reported preclinical — direct research and development expenses of $32.25K in Q4 2025.

How has LBRX's preclinical — direct research and development expenses changed year-over-year?

LBRX's preclinical — direct research and development expenses decreased by 93.0% year-over-year, from $461.25K to $32.25K.

What does preclinical — direct research and development expenses mean?

This metric represents the direct costs incurred by the company specifically for research and development activities within the preclinical stage of drug discovery. It captures expenditures related to laboratory testing, animal studies, and early-stage development efforts required to advance a therapeutic candidate toward clinical trials. Monitoring these costs provides insight into the company's investment in its early-stage pipeline and the efficiency of its discovery-phase operations.